MRDR
Myeloma and Related Disease Registry
Trial summary:
This observational study is collecting information from patients to form the Myeloma and Related Diseases Registry (MRDR)
Receptor status / problem studied:
Multiple Myeloma Plasmacytoma Plasma cell leukaemia Monoclonal gammopathy of undetermined significance (MGUS)
Inclusion criteria
- Patients with a new diagnosis of multiple myeloma, plasmacytoma, plasma cell leukaemia or monoclonal gammopathy of undetermined significance (MGUS). Diagnosis within 3 months prior to HREC approval at a site for myeloma, plasmacytoma, plasma cell leukaemia and within 5 years for MGUS in order to minimise retrospective data collection.
Exclusion criteria
- People who decline to participate in the registry.
Open for recruitment
Trial Title
MRDR
Diagnosis
Multiple myeloma
Type of trial
Collaborative
Type of treatement
Haematology
Phase
Registry
Locations
Investigators
Principal Investigator